US 12,144,800 B2
Inhibiting germination of Clostridium perfringens spores to reduce necrotic enteritis
Ernesto Abel-Santos, Las Vegas, NV (US); Norma Ramirez, Guanajuato (MX); and Marc Liggins, Irvine, CA (US)
Assigned to THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS, Las Vegas, NV (US)
Filed by The Board of Regents of the Nevada System of Higher Education on Behalf of the University of Nevada, Las Vegas, Las Vegas, NV (US)
Filed on Feb. 4, 2021, as Appl. No. 17/168,155.
Application 17/168,155 is a continuation of application No. 16/236,919, filed on Dec. 31, 2018, granted, now 10,945,996.
Application 16/236,919 is a continuation of application No. 15/545,645, abandoned, previously published as PCT/US2016/016848, filed on Feb. 5, 2016.
Claims priority of provisional application 62/113,184, filed on Feb. 6, 2015.
Prior Publication US 2021/0228550 A1, Jul. 29, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/428 (2006.01); A23K 20/195 (2016.01); A61K 9/00 (2006.01); A61K 9/14 (2006.01); A61K 45/06 (2006.01); A61K 9/16 (2006.01)
CPC A61K 31/428 (2013.01) [A23K 20/195 (2016.05); A61K 9/0056 (2013.01); A61K 9/14 (2013.01); A61K 45/06 (2013.01); A61K 9/1611 (2013.01)] 19 Claims
 
1. A method for preventing a disease caused by infection by Clostridium perfringens in a subject, the method comprising administering to the subject an effective amount of a compound having a structure represented by a formula:

OG Complex Work Unit Chemistry
wherein Q is selected from O, S, and NR3:
wherein R3, when present, is selected from hydrogen and C1-C8 alkyl;
wherein Z is selected from O, S, and NR4:
wherein R4, when present, is selected from hydrogen and C1-C8 alkyl;
wherein R1 is selected from hydrogen, C1-C8 alkyl, C1-C8 haloalkyl, —CR5aR5b(C═O)NHN═CR6Ar1, Cy1, and Ar2, provided that if Q is NR3 then R1 is not-CR5aR5b(C═O)NHN═CR6Ar1:
wherein each of R5a and R5b, when present, is independently selected from hydrogen and C1-C4 alkyl;
wherein R6, when present, is selected from hydrogen and C1-C4 alkyl;
wherein Cy1 is selected from C3-C7 cycloalkyl and C2-C7 heterocycloalkyl and substituted with 0, 1, or 2 groups independently selected from halogen, —OH, —CN, —NO2, —NH2, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 alkylamino, and (C1-C4)(C1-C4) dialkylamino;
wherein Ar1 is selected from aryl and heteroaryl and substituted with 0, 1, or 2 groups independently selected from halogen, —OH, —CN, —NO2, —NH2, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 alkylamino, and (C1-C4)(C1-C4) dialkylamino;
wherein Ar2 is selected from aryl and heteroaryl and substituted with 0, 1, or 2 groups independently selected from halogen, —OH, —CN, —NO2, —NH2, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 alkylamino, and (C1-C4)(C1-C4) dialkylamino; and
wherein each of R2a, R2b, R2c, and R2d is hydrogen,
thereby preventing the disease caused by infection by Clostridium perfringens in a subject.